Chengdu Antergen Biological Technology

Chengdu Antergen Biological Technology is a Chinese biotechnology company specializing in the research, development, and manufacturing of innovative bacterial vaccines. Founded in 2012 and now a subsidiary of Aim Vaccine, the company focuses on high-end conjugate vaccines targeting significant public health threats such as pneumococcal and meningococcal diseases. Its lead candidate is a 13-valent pneumococcal conjugate vaccine (PCV13) currently in Phase 3 clinical trials, alongside a robust pipeline including a 24-valent pneumococcal vaccine and a Staphylococcus aureus vaccine. Antergen utilizes proprietary platforms for high-efficiency protein expression and complex polysaccharide-protein conjugation to produce affordable, high-quality biologics. The company operates out of Chengdu, Sichuan, and plays a key role in the domestic Chinese vaccine market's transition toward advanced multi-valent products. Through its integration with Aim Vaccine, Antergen benefits from large-scale manufacturing capabilities and an extensive commercialization network across China.